ClinicalTrials.gg
RecruitingNCT05491798Updated Jan 5, 2024

A Big Data-based Cohort Study for Cataract Patients

An observational study in Cataract and Retina Disorder, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Sun Yat-sen University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Cataract by Sun Yat-sen University — 3 open to participants now, 4 under way, none of them phase 3. Cataract · Sun Yat-sen University.

Planned enrollment
5th of 17
1,000 · median 428
Started
2020
with 4 others
Observational
17 of 52
1 open now
Registered
44th of 52
by date

Among the 52 studies in Cataract by Sun Yat-sen University, this one is the 5th largest by planned enrollment of the 17 observational ones that give a count, is one of 5 that started in 2020, is one of 17 observational ones, and was the 44th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

3 of the 52 studies in Cataract by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Cataract by Sun Yat-sen University, or all of them as a file.
02

Study summary

Cataract is an important cause of blindness and visual impairment worldwide. At present, the only effective treatment method is surgery. The visual function of most patients can be significantly improved after surgery, but there are still 5-20% of patients whose visual function cannot be improved after surgery. Previous studies have found that the surgical complications and postoperative visual function of cataract patients are closely related to the condition of the fundus, but the current fundus camera cannot perform clear fundus imaging of cataract patients, and the existing potential visual inspections, such as retinal visual inspection, are also inaccurate. Predict postoperative visual acuity. Therefore, there is an urgent need for a reliable postoperative effect prediction system for cataract patients to provide reference for both ophthalmologists and patients.

This study intends to collect patient medical record information and traditional/ultra-wide fundus photos and other multi-modal data. Firstly, this study will use artificial intelligence technology to enhance fundus photos of cataract patients to obtain clearer fundus photos. Then this study will use both medical record information and traditional/ultra-wide fundus photographs to predict postoperative vision and visual function of cataract patients.

03

Conditions studied

  • Cataract
  • Retina Disorder

Keywords

  • Cataract
  • Postoperative prediction
  • Image enhancement
  • Retina disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All candidates for cataract surgery (phacoemulsification and intraocular lens implantation) within a week.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Candidates for cataract surgery (phacoemulsification and intraocular lens implantation) within a week.

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to receive fundus photography
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
1 Week
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Change of best corrected visual acuity

    Change of best corrected visual acuity from baseline to 1 week after surgery

    Time frame: Baseline and 1 week after surgery

  2. Accuracy for detection of retinal disorders

    Accuracy for detection of retinal disorders using enhanced fundus images

    Time frame: 1 week after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Dec 2024, 53 months after the start.

Of 169 non-industry observational studies under Cataract, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 30. This study's planned 53 months is above that.

Counting every sponsor, half of 236 studies reached it within 16 months; a quarter within 9 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2021
First posted
Aug 8, 2022
StartActual
Jul 1, 2020
Primary completionEst.
Dec 2024
CompletionEst.
Jun 2025
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05491798
Responsible party
Haotian Lin (Clinical Professor, Sun Yat-sen University) — Principal investigator
First posted
Aug 8, 2022
Start date
Jul 1, 2020
Primary completion
Dec 2024 (estimated)
Completion
Jun 2025 (estimated)
Last update
Jan 5, 2024

Study contacts

Haotian Lin, M.D., Ph.D.
Contact
linht5@mail.sysu.edu.cn
8613802793086
Haotian Lin, M.D., Ph.D.
principal investigator · Zhongshan Ophthalmic Center, Sun Yat-sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion